| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Operating Activities | ||||||
Net income (loss) | ||||||
-40,448 | -53,689 | 6,973 | - | |||
Net loss | ||||||
- | - | - | -112,415 | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Stock-based compensation | ||||||
1,598 | 2,140 | 4,884 | 3,809 | |||
Depreciation and amortization | ||||||
2,235 | 2,390 | 3,127 | 3,362 | |||
Non-cash interest expense and other | ||||||
699 | 988 | 636 | - | |||
Gain on milestone payment related to sale of Hyperimmune Business | ||||||
4,250 | - | 52,697 | - | |||
Impairment of goodwill and intangible assets | ||||||
- | - | - | 71,013 | |||
Income taxes | ||||||
- | - | - | -15,817 | |||
Change in fair value of contingent consideration | ||||||
- | - | - | -444 | |||
Changes in operating assets and liabilities: | ||||||
Accounts receivable | ||||||
1,802 | 3,079 | 1,834 | -2,172 | |||
Inventories | ||||||
4,354 | 757 | 567 | -13,683 | |||
Income taxes | ||||||
- | - | - | 1,376 | |||
Prepaid expenses and other current assets | ||||||
-3,614 | 1,315 | 1,628 | 3,223 | |||
Operating lease right of use asset | ||||||
945 | - | - | - | |||
Accounts payable, accrued compensation and other liabilities | ||||||
938 | 1,279 | 195 | - | |||
Long-term operating lease liability | ||||||
1,039 | -621 | - | - | |||
Restricted cash | ||||||
- | - | - | 400 | |||
Sales rebates and discounts | ||||||
519 | - | -345 | -997 | |||
Assets and liabilities held for sale and amount due to Saol | ||||||
- | - | 2,700 | - | |||
Deferred revenue | ||||||
- | - | -3,707 | - | |||
Accounts payable, accrued compensation and other liabilities | ||||||
- | - | - | 2,479 | |||
Net cash used in operating activities | ||||||
-42,383 | -51,422 | -41,573 | - | |||
Investing Activities | ||||||
Deferred revenue | ||||||
- | - | - | -3,454 | |||
Net cash used in operating activities | ||||||
- | - | - | -36,862 | |||
Proceeds from the maturity of investments | ||||||
- | 90,243 | 70,730 | - | |||
Cash received from sale of Aptevo BioTherapeutics | ||||||
4,250 | 65 | 59,763 | - | |||
Purchases of property and equipment | ||||||
153 | 976 | 1,402 | 2,512 | |||
Purchases of investments | ||||||
- | 16,535 | 99,633 | 44,882 | |||
Net cash (used in) provided by investing activities | ||||||
4,097 | 72,797 | 29,458 | - | |||
Financing Activities | ||||||
Common stock issued upon exercise of stock options, and under the ATM arrangement, net | ||||||
- | - | 442 | - | |||
Payment of tax liability for vested equity awards | ||||||
58 | 808 | 758 | - | |||
Payments of long-term debt, issuance costs and modification fees | ||||||
-137 | - | - | 18,038 | |||
Proceeds from issuance or exercise of common stock, warrants, and pre-funded warrants | ||||||
20,344 | 623 | - | - | |||
Proceeds from exercise of common stock options | ||||||
- | - | - | 38 | |||
Fees paid to lender to amend debt agreement | ||||||
- | 602 | 150 | - | |||
Net cash provided by (used in) investing activities | ||||||
- | - | - | -47,394 | |||
Transfer from former parent, prior to spin-off | ||||||
- | - | - | 71,219 | |||
Settlement of contribution receivable from former parent | ||||||
- | - | 20,000 | - | |||
Net cash provided by (used in) financing activities | ||||||
20,149 | -787 | 19,534 | - | |||
Net cash (used in) provided by financing activities | ||||||
- | - | - | 89,295 | |||
Increase (decrease) in cash, cash equivalents, and restricted cash | ||||||
-18,137 | 20,588 | 7,419 | - | |||
(Decrease) increase in cash and cash equivalents | ||||||
- | - | - | 5,039 | |||
Cash paid for interest | ||||||
- | - | 1,778 | - | |||
Cash paid for interest | ||||||
- | - | - | 537 | |||
Cash paid for taxes | ||||||
- | - | - | 162 | |||